他泽司他能有效治病吗？

Introduction: Tazerestat, a potent and selective oral EZH2 inhibitor, demonstrated anti-tumor activity in a Phase 1 study of patients with DLBCL including mutant (mt) or wild-type (wt) EZH2 tumors, for the treatment of adults and adolescents 16 years of age and older with unresectable locally advanced or metastatic epithelioid sarcoma.

Can the generic version of tazerestat also be effective in treating diseases?

Currently, there are no generic drugs on the market. The more common one is the generic version of Lucius Pharmaceutical Factory in Laos, which can also effectively treat related diseases. The development of generic drugs requires rigorous research and testing to ensure that their safety and effectiveness are equivalent to those of the original drugs. Lucius Laos's generic version of tazerestat has been approved for marketing by relevant departments, and its drug ingredients, efficacy, etc. are basically the same as the original drugs.

Efficacy of tazerestat

In an open-label, multicenter phase 2 study, tazerestat is being evaluated in patients with mt or wt EZH2 R/R DLBCL or follicular lymphoma (grade 1-3b). Tazerestat 800 mg twice daily; prednisolone was administered on days 1-5 and 15-19 in a 28-day cycle lasting 16 weeks. Assess every 8 weeks using the IWG-NHL assessment criteria (Cheson 2007).

The interim phase 2 safety and activity data of 226 DLBCL patients were summarized. The ORR of the tazerestat mt group and wt group were both 17%, and the ORR of the prednisolone group was 9%. Notably, the DOR was significantly higher in the mt group.

Tazerestat at 800 mg doses, either alone or in combination with prednisolone, was generally well tolerated, with clinical activity observed in approximately 20% of monotherapy patients, regardless of mutational status, many of whom had received multiple prior therapies. The combination of tazetostat and prednisolone did not result in improved activity compared with tazeretostat monotherapy.

Tazerestat Precautions

1. Tazerestat may increase the risk of secondary malignant tumors in patients, including T-cell lymphoblastic lymphoma, myelodysplastic syndrome and acute myeloid leukemia. Therefore, long-term monitoring of patients for the development of secondary malignancies is required.

2. During treatment with tazerestat, you should avoid eating grapefruit and drinking grapefruit juice, and avoid taking St. John's wort.

3. If certain side effects occur, the doctor may change the dose, temporarily stop or completely stop treatment with tazerestat.

Tazerestat may cause harm to the fetus. Pregnant women should be informed of the potential risks when using it, and female patients of childbearing potential are advised to take effective contraceptive measures during treatment with tazerestat and for 6 months after the last dose.